Még nem toboroz
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015· 3. fázis· Boehringer Ingelheim· Forrás
Contact: Boehringer Ingelheim
Még nem toboroz
A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy
2026-527617-29-00· 3. fázis· Systimmune Inc.· Forrás
Toboroz
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· 3. fázis· Takeda· Forrás
Toboroz
Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis
NCT07686081· 3. fázis· Vanda Pharmaceuticals· Forrás
Toboroz
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
NCT07737743· 2. fázis· Novartis Pharmaceuticals· Forrás
Még nem toboroz
A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)
NCT07760818· 2. fázis· argenx· Forrás
Toboroz
A study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflammation in adult participants with moderately to severely active rheumatoid arthritis.
2025-522076-85-00· 2. fázis· AstraZeneca AB· Forrás
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás
Toboroz
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07509307· 3. fázis· Novo Nordisk A/S· Forrás
Toboroz
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181· 2. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07481630· 3. fázis· Novo Nordisk A/S· Forrás
Még nem toboroz
A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate response to methotrexate and tumor necrosis factor inhibition (START SYNERGY)
2025-524005-32-00· 2. fázis· Elevara Medicines Limited· Forrás
Toboroz
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
NCT07404865· 3. fázis· Vor Biopharma· Forrás
Toboroz
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
NCT07047690· 2. fázis· Galderma R&D· Forrás
Toboroz
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
NCT07201129· 3. fázis· Viatris Innovation GmbH· Forrás
Toboroz
Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared with Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-
Negative Adult Subjects with Chronic Hepatitis B (B-SUPREME)
2025-521178-33-00· 2. fázis· Aligos Therapeutics Inc.· Forrás
Toboroz
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318· 3. fázis· Takeda· Forrás
Fut, nem toboroz
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
NCT07211633· 3. fázis· TG Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744· 3. fázis· AbbVie· Forrás
Toboroz
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357· 3. fázis· Biogen· Forrás
Toboroz
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285· 3. fázis· Takeda· Forrás
Toboroz
Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
2024-511346-39-00· 1. fázis· Chugai Pharmaceutical Co. Ltd.· Forrás
Toboroz
Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures
2024-514499-42-00· 3. fázis· Neuraxpharm Pharmaceuticals S.L.· Forrás
Toboroz
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235· 3. fázis· Takeda· Forrás
Toboroz
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
NCT06641414· 3. fázis· Ascentage Pharma Group Inc.· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824· 3. fázis· Genmab· Forrás
Fut, nem toboroz
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499· 3. fázis· argenx· Forrás
Toboroz
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· 3. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06311721· 3. fázis· Amgen· Forrás
Fut, nem toboroz
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2024-510965-41-00· 3. fázis· AbbVie Deutschland GmbH & Co. KG· Forrás
Toboroz
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417· 1. fázis· Chugai Pharmaceutical· Forrás
Toboroz
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects
with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
2024-511309-47-00· 2. fázis· Karyopharm Therapeutics Inc.· Forrás
Toboroz
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744· 3. fázis· Genmab· Forrás
Fut, nem toboroz
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.
2022-501622-37-00· 3. fázis· Celltrion Inc.· Forrás
Fut, nem toboroz
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486· 3. fázis· Sanofi· Forrás
Toboroz
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566· 3. fázis· Ascentage Pharma Group Inc.· Forrás
Fut, nem toboroz
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: SUCCESSOR-2
2022-500861-29-00· 3. fázis· Celgene Corp.· Forrás
Toboroz
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
NCT05645107· 3. fázis· Grifols Therapeutics LLC· Forrás
Fut, nem toboroz
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
NCT05429268· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
NCT05540327· 2. fázis· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Forrás
Showing 50 of 70.